

For someone living with PMR, prednisone can feel almost miraculous. The pain and stiffness that made getting out of bed, raising your arms, or getting out of a chair nearly impossible may improve dramatically after treatment begins. That rapid response is one of the characteristic features of PMR and can be incredibly meaningful for someone whose daily life has been disrupted by the disease.
But once you start feeling better, an important question follows: When can I stop taking the prednisone?
The answer is rarely, “As soon as you feel better.”
Insights From People Who Help Patients Taper
CreakyJoints talked with Kyle George, PA-C, and Wendy Simmons, PA-C, about one of the most common questions people with polymyalgia rheumatica (PMR) ask once prednisone starts working: When can I stop? Kyle and Wendy are rheumatology physician assistants and RhAPP (Rheumatology Advanced Practice Providers) board members who help people with PMR manage steroid treatment every day. They know how to balance keeping inflammation under control while lowering the risks of long-term steroid use. This article draws on our conversation with them about why tapering takes time and how to stay on track along the way.
There’s No One-Size-Fits-All Taper
Prednisone is generally intended to control the inflammation of PMR and then be gradually reduced to the lowest effective dose while minimizing both disease relapse and steroid-related complications. Current recommendations from EULAR, an organization that brings together patients, healthcare professionals, and researchers to improve care for people with rheumatic disease, emphasize individualized treatment and gradual tapering rather than one fixed schedule that works for every patient. Recent research reinforces this approach: studies of PMR tapering strategies have found considerable variation in how quickly steroids are reduced, with insufficient evidence to identify one universally optimal tapering schedule.
What a Taper Might Look Like
A common approach: 15 mg → 12.5 mg → 10 mg → 1 mg increments
Kyle George, PA, describes a practical tapering approach that may look something like 15 mg of prednisone daily, followed by 12.5 mg, then 10 mg, and subsequently decreasing by approximately 1 mg at a time. This illustrates an important principle that as the prednisone dose gets lower, reductions may become smaller and more gradual.
However, this should not be interpreted as a universal prescription. The appropriate dose and pace depend on the individual, including symptom response, inflammatory markers when clinically appropriate, duration of treatment, previous relapses, comorbidities, and risk for steroid complications. Current guidance supports tailoring the taper to the patient’s disease course and response.
Why Feeling Better Isn’t a Reason to Stop Treatment
One of the most important things to understand about prednisone is that symptom improvement and adrenal recovery are not the same thing. When steroids are taken for a prolonged period, they can suppress the body’s hypothalamic-pituitary-adrenal (HPA) axis. In other words, the body becomes accustomed to receiving cortisol-like medication from an outside source and may temporarily reduce its own cortisol production. If prednisone is reduced too quickly or stopped abruptly after prolonged treatment, a person can develop symptoms of steroid withdrawal or, in some circumstances, clinically significant adrenal insufficiency.
That is why a patient should never independently speed up a taper simply because PMR symptoms have improved. Feeling dramatically better is wonderful news, but it is not a signal to stop prednisone without medical guidance. Instead, think of tapering as a partnership between controlling the disease and protecting the body.
The Balancing Act: Disease Control Versus Steroid Exposure
Taking steroids for a long time may increase the chance of certain side effects and health problems.
Possible side effects include:
- confusion
- excitement
- restlessness
- mood changes
- depression
- headache
- nausea
- vomiting
- thinning skin
- acne
- trouble sleeping
- weight gain
- high blood glucose (diabetes)
- allergic reactions
Long-term use of steroids may raise the risk of:
- osteoporosis or bone loss
- increased risk of infections
- cataracts or glaucoma
- diabetes
Kyle George emphasizes that more prednisone isn’t necessarily better.
“Bigger is not always better necessarily when it comes to steroids.”
The goal is not to remain on prednisone indefinitely, but neither is the goal to get off prednisone as quickly as possible. The goal is to use the lowest effective dose for the appropriate amount of time, while monitoring for recurrence of PMR symptoms and minimizing unnecessary steroid exposure.
When Steroids Alone Aren’t Enough
For people who experience repeated relapses or who are at particularly high risk for steroid complications, clinicians may also consider steroid-sparing therapies. Depending on the individual clinical situation, options may include methotrexate or therapies targeting the interleukin-6 (IL-6) pathway.
Make Taking Prednisone Part of Your Routine
Kyle George, PA, also emphasizes a surprisingly simple strategy: keep your prednisone somewhere connected to something you never forget.
For example, if you routinely take your prednisone in the morning, you might keep it near your toothbrush or another item that is part of your established morning routine. The goal is to create a consistent environmental reminder so taking your medication becomes automatic. Kyle recommends connecting prednisone to something you already do every day.
“Tie the bottle to your toothbrush or another routine.”
Keeping your prednisone somewhere you will see it as part of your daily routine can serve as a simple reminder to take it as prescribed.
A printed taper schedule can also be extremely helpful. Write down each dose and the date you are supposed to decrease it. Checking off each day can reduce confusion, particularly when the dose changes frequently. Most importantly, keep your healthcare professional involved throughout the process.
What to Do If Your Symptoms Come Back
If symptoms return during a taper, such as increasing shoulder or hip-girdle pain and stiffness, difficulty with previously manageable activities, or other concerning symptoms, contact your healthcare professional rather than simply increasing or decreasing prednisone on your own.
Slow and steady is the point
Tapering prednisone can sometimes feel frustrating. You may feel ready to move faster because you’re finally feeling like yourself again, but PMR treatment is not a race. A thoughtful taper gives your healthcare professional an opportunity to balance disease control, adrenal recovery, relapse prevention, and minimizing cumulative steroid exposure. Research continues to show that there is no single tapering schedule that is perfect for every person with PMR.
If prednisone has given you your mobility back, the next goal is not simply to stop it. The goal is to come down safely, thoughtfully, and with a plan. Slow and steady isn’t a failure to get off steroids, but it’s part of getting off them safely.
You can learn more about PMR here.
Interested in trying PatientSpot to track symptoms?
Create a free account at PatientSpot.org and begin tracking your symptoms today.
Are you interested in more resources about polymyalgia rheumatica (PMR)? Enter your email below to subscribe and receive our newsletter and resources!
Coskun Benlidayi, I. (2024). Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: A narrative review. Clinical Rheumatology, 43, 17–27. https://doi.org/10.1007/s10067-023-06708-3
Creaky Staff. (2018, October 29). How corticosteroids for arthritis affect your infection risk. CreakyJoints. https://creakyjoints.org/living-with-arthritis/treatment-and-care/medications/corticosteroids-infection-risk/
Dejaco, C., Matteson, E. L., Buttgereit, F., Dasgupta, B., & other members of the EULAR task force. (2026). 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2025-227376
Espígol-Frigolé G, Dejaco C, Mackie SL, et al. Polymyalgia rheumatica. Lancet. 2023;402(10411):1459-1472. https://pubmed.ncbi.nlm.nih.gov/37832573/
Feroze, K. B., Zeppieri, M., & Khazaeni, L. (2023). Steroid-induced glaucoma. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430903/
George A, et al. An update on polymyalgia rheumatica. J Intern Med. 2022. https://pubmed.ncbi.nlm.nih.gov/35612524/
Ince, S. (2019, August 23). 7 myths about corticosteroids rheumatologists want to clear up, once and for all.CreakyJoints. https://creakyjoints.org/living-with-arthritis/treatment-and-care/medications/corticosteroid-myths/
Jian, Y.-F., Zhang, J.-S., & Wan, X.-H. (2025). Cataract induced by glucocorticoids. Clinical Ophthalmology, 19, 3703–3712. https://pmc.ncbi.nlm.nih.gov/articles/PMC12513239/
Kooijman, N. E. S. E. P., van den Bemt, B. J. F., van Bon, L., Brouwer, E., van der Maas, A., & Wientjes, M. H. M. (2026). Glucocorticoid tapering strategies in polymyalgia rheumatica: A systematic literature review. Rheumatology, 65(2), keag056. https://pubmed.ncbi.nlm.nih.gov/41678240/
Li J, Hall J, Dafoe W, Yacyshyn E. Rates of glucocorticoid taper in the management of polymyalgia rheumatica: the science behind the “art”. Clin Rheumatol. 2025;44(1):105-113. https://pubmed.ncbi.nlm.nih.gov/39641835/
Lundberg, I. E., Sharma, A., Turesson, C., & Mohammad, A. J. (2022). An update on polymyalgia rheumatica. Journal of Internal Medicine, 292(5), 717–732. https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13525
Marcin, A. (2023, May 26). Understanding how steroids cause osteoporosis. Healthline. https://www.healthline.com/health/osteoarthritis/how-do-steroids-cause-osteoporosis
Michet, C. J., & Matteson, E. L. (2008). Polymyalgia rheumatica. BMJ, 336(7647), 765–769. https://pmc.ncbi.nlm.nih.gov/articles/PMC2287267
Mukhtyar CB, et al. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Ann Rheum Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/42481270/
National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2022). Polymyalgia rheumatica and giant cell arteritis. National Institutes of Health. https://www.niams.nih.gov/health-topics/polymyalgia-rheumatica-giant-cell-arteritis
Priya, G., Laway, B. A., Ayyagari, M., Gupta, M., Bhat, G. H. K., & Dutta, D. (2024). The glucocorticoid taper: A primer for the clinicians. Indian Journal of Endocrinology and Metabolism, 28(4), 350–362. https://pmc.ncbi.nlm.nih.gov/articles/PMC11451960/
Tanaka Y, et al. Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: A cohort study using routinely collected health data. Joint Bone Spine. 2024;91(3):105680. https://pubmed.ncbi.nlm.nih.gov/38143016/
Yasir, M., Goyal, A., & Sonthalia, S. (2023). Corticosteroid adverse effects. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK531462/




